Orthocell (ASX:OCC) share price surges 13% on study success

Shares in the medical company are surging today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Orthocell Ltd (ASX: OCC) share price is soaring today following news of clinical study success.

At the time of writing, the Orthocell share price is trading hands at 58 cents, up 12.62%.

Orthocell is developing new medical devices and cellular therapies to help people recover from injury.

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition

Image source: Getty Images

Why is the share price surging?

It appears investors are responding to positive results from a clinical trial into the use of one of Orthocell's lead products, OrthoATI.

In today's release, Orthocell said its data confirmed this product could safely reduce pain in patients suffering from rotator cuff tears. OrthoATI is more effective than steroid injections for treating this injury, according to the company.

Orthocell now plans to speed up its commercialisation plans for OrthoATI in the United States, including conducting a study in front of the Food and Drug Administration.

Orthocell told the market today it believed it could use its OrthoATI treatment to help 480,000 patients per year in the US alone. The company sees this as a US$4 to $5 billion market opportunity (AU $5.6 to $7 billion).

Management commentary

Orthocell managing director Paul Anderson welcomed the news, saying it was an important milestone. He added:

We are absolutely delighted with the study results for this challenging and debilitating condition which clearly demonstrates that OrthoATI is more effective than steroid injection for treatment of rotator cuff tendinopathy with intrasubstance tendon tear.

We are now in a very strong position to progress our US commercialisation strategy to deliver the first injectable cell therapy in orthopaedics that truly addresses the cause of degeneration and returns patients to full use of their chronically damaged tendons.

Orthocell share price snapshot

The Orthocell share price has lifted more than 38% in the past 12 months and is up 27.78% this year to date.

In contrast, the benchmark S&P/ASX 200 Index (ASX: XJO) has returned nearly 11% in the past year.

Shares in the company reached a 52-week high of 66 cents, while the low was 40.5 cents.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Falling pills in a blue background.
Healthcare Shares

This ASX healthcare company's profit has rocketed 24%

Expansion into new markets is paying off.

Read more »

Doctor checking patient's spine x-ray image.
Healthcare Shares

Are these rocketing ASX healthcare shares a must buy?

These companies all rose significantly to start the week.

Read more »

A doctor and an elderly couple sit at a desk and look at a lung scan uploaded.
Healthcare Shares

Why did 4DMedical shares charge higher today, then drop?

The company's key technology has received a big tick.

Read more »

Business woman working from home with stock market chart showing percent change on her laptop screen.
Healthcare Shares

Should I invest $10,000 in CSL shares before the end of May?

This ASX healthcare giant has fallen hard, but the lower price and improving dividend appeal make it worth another look.

Read more »

A woman wakes up after sleeping soundly, stretching her arms high sitting in bed.
Healthcare Shares

Why this fallen ASX 200 blue chip could be a strong buy

I think the market may be underestimating the durability of this healthcare business.

Read more »

Female pharmacist smiles with a digital tablet.
Broker Notes

3 reasons to buy Sigma Healthcare shares today

A leading analyst expects “impressive growth” from Sigma Healthcare shares.

Read more »

A young woman lifts her red glasses with one hand as she takes a closer look at news.
Healthcare Shares

Could this fallen ASX 200 stock be a once-in-a-decade opportunity?

The valuation now looks far more interesting for a healthcare stock with a global leadership position.

Read more »

Hand dropping a mic.
Healthcare Shares

Pro Medicus shares jump as massive US contract win turns heads

Pro Medicus shares are rocketing after a major US win.

Read more »